Bone density during rapid weight loss: what is known, which is less than you would hope
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
Trial design
Page 22 of 32 of this archive, newest first.
STEP 3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why "muscle-sparing" is a marketing term and not a measurement
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Wuhan: 24 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Qingdao: 22 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
From the floor in Changsha: 21 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The one randomised trial that combined an incretin with supervised exercise
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
From the floor in Suzhou: 6 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Why the bone question is harder than the muscle question
What the Journal would want measured before treating this as settled in either direction.
From the floor in Shenzhen: 5 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.